Adenine derivatives
This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR 3 (wherein R 3 represents a hydrogen atom or C 1-3 alkyl) or the like; R 1 represents substituted or unsubstituted alkyl or the like; R 2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.
1. An adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by formula (I):
wherein X represents NR 3 (wherein R 3 represents a hydrogen atom or C 1-3 alkyl), an oxygen atom, or a sulfur atom; R 1 represents substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted cycloalkenyl; R 2 represents hydroxyl, mercapto, C 1-8 acyloxy, or C 2-8 alkoxycarbonyloxy; and Y represents a substituted or unsubstituted naphthalene ring, a substituted or unsubstituted 5- or 6-membered monocyclic aromatic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of nitrogen, oxygen, and sulfur atoms, or a substituted or unsubstituted fused bicyclic aromatic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of nitrogen, oxygen, and sulfur atoms.
2. The compound according to claim 1 , wherein, in formula (I), R 1 represents C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 2-8 alkoxyalkyl, C 1-8 hydroxyalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl or cycloalkenyl.
3. The compound according to claim 1 , wherein, in formula (I), R 1 represents C 1-6 alkyl, cycloalkyl, or cycloalkenyl.
4. The compound according to claim 1 , wherein, in formula (I), X represents NH.
5. The compound according to claim 1 , wherein, in formula (I), X represents an oxygen atom.
6. The compound according to claim 1 , wherein, in formula (I), Y represents a unsubstituted or substituted pyridine ring or a substituted or unsubstituted pyrazine ring.
7. The compound according to claim 1 , wherein, in formula (I), Y represents a unsubstituted or substituted naphthalene ring or a substituted or unsubstituted thiophene ring.
8. The compound according to claim 1 , wherein, in formula (I), Y has 1 to 4 substituents when Y is a pyridine ring, and 1 to 3 substituents when Y is a pyrazine ring at any positions, wherein the substituent is selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, hydroxyl, mercapto, C 1-4 alkylthio, a halogen atom, amino, C 2-8 dialkylamino, C 1-4 monoalkylamino, pyrrolidinyl, piperidino, and morpholino.
9. The compound according to claim 1 , wherein, in formula (I), Y represents a pyridine ring which may have a substituent selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, hydroxyl, mercapto, C 1-4 alkylthio, a halogen atom, amino, C 2-8 dialkylamino, C 1-4 monoalkylamino, pyrrolidinyl, piperidino, and morpholino; R 1 represents C 1-6 alkyl; and R 2 represents hydroxyl.
10. The compound according to claim 9 , wherein, in formula (I), X represents NH or an oxygen atom.
11. 2-Butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising the compound according to any one of claims 1 to 10 or 11 as an active ingredient, and a carrier.